JAK/STAT Signaling


Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
-
A8367 AST-1306Summary: EGFR/HER2 inhibitor -
A8375 AZD8931 (Sapitinib)Target: EGFR|ErbBSummary: ErbB inhibitor -
B3227 CNX-2006Summary: mutant-EGFR inhibitor, selective and irreversible -
B1495 OSI-420 free baseSummary: EGFR inhibitor -
B1020 AST-1306 TsOHSummary: ErbB2 and EGFR inhibitor -
B6116 GLPG0634 analogueSummary: JAK1 inhibitor, potent and selective -
B4764 TCS-PIM-1-4aSummary: Pim inhibitor -
B4789 SH-4-541 CitationTarget: STATSummary: STAT inhibitor, potent -
B4836 CPI-360Summary: EZH2 inhibitor -
B4913 Corylifol ASummary: STAT3 inhibitor

